AHEAD-MERIT: first-line pembrolizumab and BNT113 in advanced HPV16+ HNSCC

Nabil Saba, MD, Winship Cancer Institute of Emory University, Atlanta, GA, discusses the safety and efficacy results from the ongoing Phase II AHEAD-MERIT trial (NCT04534205) of BNT113, an investigational mRNA-lipoplex cancer vaccine targeting HPV16 E6 and E7 oncoproteins, with pembrolizumab in patients with unresectable recurrent or metastatic HPV16+ PD-L1+ head and neck squamous cell carcinoma (HNSCC). In the safety run-in cohort, the combination showed promising efficacy, and BNT113 was well tolerated, with treatment-related adverse events primarily being mild to moderate. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.